There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rocket Pharmaceuticals (RCKT) and Cardiff Oncology (CRDF) with bullish sentiments.
Rocket Pharmaceuticals (RCKT)
Needham analyst Gil Blum reiterated a Buy rating on Rocket Pharmaceuticals today and set a price target of $75.00. The company’s shares closed last Tuesday at $42.07.
According to TipRanks.com, Blum is ranked #6791 out of 7451 analysts.
Currently, the analyst consensus on Rocket Pharmaceuticals is a Strong Buy with an average price target of $71.50, implying a 70.0% upside from current levels. In a report issued on April 1, Leerink Partners also maintained a Buy rating on the stock with a $66.00 price target.
See today’s analyst top recommended stocks >>
Cardiff Oncology (CRDF)
In a report released yesterday, Jason McCarthy from Maxim Group reiterated a Buy rating on Cardiff Oncology, with a price target of $30.00. The company’s shares closed last Tuesday at $8.56.
According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 35.9% and a 46.9% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Brainstorm Cell Therapeutics, and Lineage Cell Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cardiff Oncology with a $27.33 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
